As of 2025-07-15, the EV/EBITDA ratio of Lexicon Pharmaceuticals Inc (LXRX) is -2.84. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LXRX's latest enterprise value is 466.36 mil USD. LXRX's TTM EBITDA according to its financial statements is -164.27 mil USD. Dividing these 2 quantities gives us the above LXRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.3x - 13.6x | 13.4x |
| Forward P/E multiples | 18.1x - 33.0x | 20.6x |
| Fair Price | (8.28) - (6.27) | (7.79) |
| Upside | -801.8% - -631.7% | -760.5% |
| Date | EV/EBITDA |
| 2025-07-14 | -2.84 |
| 2025-07-11 | -2.62 |
| 2025-07-10 | -2.73 |
| 2025-07-09 | -2.60 |
| 2025-07-08 | -2.26 |
| 2025-07-07 | -2.16 |
| 2025-07-03 | -2.22 |
| 2025-07-02 | -2.26 |
| 2025-07-01 | -2.18 |
| 2025-06-30 | -2.32 |
| 2025-06-27 | -2.05 |
| 2025-06-26 | -2.28 |
| 2025-06-25 | -2.22 |
| 2025-06-24 | -1.93 |
| 2025-06-23 | -1.85 |
| 2025-06-20 | -1.89 |
| 2025-06-18 | -1.88 |
| 2025-06-17 | -1.82 |
| 2025-06-16 | -1.71 |
| 2025-06-13 | -1.71 |
| 2025-06-12 | -1.77 |
| 2025-06-11 | -1.78 |
| 2025-06-10 | -1.78 |
| 2025-06-09 | -1.88 |
| 2025-06-06 | -1.93 |
| 2025-06-05 | -1.82 |
| 2025-06-04 | -1.69 |
| 2025-06-03 | -1.63 |
| 2025-06-02 | -1.60 |
| 2025-05-30 | -1.62 |
| 2025-05-29 | -1.69 |
| 2025-05-28 | -1.78 |
| 2025-05-27 | -1.76 |
| 2025-05-23 | -1.69 |
| 2025-05-22 | -1.69 |
| 2025-05-21 | -1.59 |
| 2025-05-20 | -1.49 |
| 2025-05-19 | -1.46 |
| 2025-05-16 | -1.41 |
| 2025-05-15 | -1.40 |
| 2025-05-14 | -1.41 |
| 2025-05-13 | -1.62 |
| 2025-05-12 | -1.72 |
| 2025-05-09 | -1.78 |
| 2025-05-08 | -1.75 |
| 2025-05-07 | -1.74 |
| 2025-05-06 | -1.68 |
| 2025-05-05 | -1.82 |
| 2025-05-02 | -1.73 |
| 2025-05-01 | -1.83 |